GIP receptor (gipr_human)
FAMILY
Class B1 (Secretin) Peptide receptors Glucagon receptor family GIP receptor
GENE
GIPR
ORGANISM
Human (Homo sapiens)
ALT. NAMES
Gastric inhibitory polypeptide receptor, GIP-R, Glucose-dependent insulinotropic polypeptide receptor
SOURCE
SWISSPROT
SEQUENCE
N-term | |||||||||
M
|
T
|
T
|
S
|
P
|
I
|
L
|
Q
|
L
|
L
|
10 |
L
|
R
|
L
|
S
|
L
|
C
|
G
|
L
|
L
|
L
|
20 |
Q
|
R
|
A
|
E
|
T
|
G
|
S
|
K
|
G
|
Q
|
30 |
T
|
A
|
G
|
E
|
L
|
Y
|
Q
|
R
|
W
|
E
|
40 |
R
|
Y
|
R
|
R
|
E
|
C
|
Q
|
E
|
T
|
L
|
50 |
A
|
A
|
A
|
E
|
P
|
P
|
S
|
G
|
L
|
A
|
60 |
C
|
N
|
G
|
S
|
F
|
D
|
M
|
Y
|
V
|
C
|
70 |
W
|
D
|
Y
|
A
|
A
|
P
|
N
|
A
|
T
|
A
|
80 |
R
|
A
|
S
|
C
|
P
|
W
|
Y
|
L
|
P
|
W
|
90 |
H
|
H
|
H
|
V
|
A
|
A
|
G
|
F
|
V
|
L
|
100 |
R
|
Q
|
C
|
G
|
S
|
D
|
G
|
Q
|
W
|
G
|
110 |
L
|
W
|
R
|
D
|
H
|
T
|
Q
|
C
|
E
|
N
|
120 |
TM1 | |||||||||
P
|
E
|
K
|
N
|
E
|
A
|
F
|
L
|
D
|
Q
|
130 |
R
|
L
|
I
|
L
|
E
|
R
|
L
|
Q
|
V
|
M
|
140 |
Y
|
T
|
V
|
G
|
Y
|
S
|
L
|
S
|
L
|
A
|
150 |
T
|
L
|
L
|
L
|
A
|
L
|
L
|
I
|
L
|
S
|
160 |
ICL1 | TM2 | ||||||||
L
|
F
|
R
|
R
|
L
|
H
|
C
|
T
|
R
|
N
|
170 |
Y
|
I
|
H
|
I
|
N
|
L
|
F
|
T
|
S
|
F
|
180 |
M
|
L
|
R
|
A
|
A
|
A
|
I
|
L
|
S
|
R
|
190 |
ECL1 | |||||||||
D
|
R
|
L
|
L
|
P
|
R
|
P
|
G
|
P
|
Y
|
200 |
L
|
G
|
D
|
Q
|
A
|
L
|
A
|
L
|
W
|
N
|
210 |
TM3 | |||||||||
Q
|
A
|
L
|
A
|
A
|
C
|
R
|
T
|
A
|
Q
|
220 |
I
|
V
|
T
|
Q
|
Y
|
C
|
V
|
G
|
A
|
N
|
230 |
Y
|
T
|
W
|
L
|
L
|
V
|
E
|
G
|
V
|
Y
|
240 |
L
|
H
|
S
|
L
|
L
|
V
|
L
|
V
|
G
|
G
|
250 |
ICL2 | TM4 | ||||||||
S
|
E
|
E
|
G
|
H
|
F
|
R
|
Y
|
Y
|
L
|
260 |
L
|
L
|
G
|
W
|
G
|
A
|
P
|
A
|
L
|
F
|
270 |
V
|
I
|
P
|
W
|
V
|
I
|
V
|
R
|
Y
|
L
|
280 |
ECL2 | |||||||||
Y
|
E
|
N
|
T
|
Q
|
C
|
W
|
E
|
R
|
N
|
290 |
TM5 | |||||||||
E
|
V
|
K
|
A
|
I
|
W
|
W
|
I
|
I
|
R
|
300 |
T
|
P
|
I
|
L
|
M
|
T
|
I
|
L
|
I
|
N
|
310 |
F
|
L
|
I
|
F
|
I
|
R
|
I
|
L
|
G
|
I
|
320 |
L
|
L
|
S
|
K
|
L
|
R
|
T
|
R
|
Q
|
M
|
330 |
TM6 | |||||||||
R
|
C
|
R
|
D
|
Y
|
R
|
L
|
R
|
L
|
A
|
340 |
R
|
S
|
T
|
L
|
T
|
L
|
V
|
P
|
L
|
L
|
350 |
G
|
V
|
H
|
E
|
V
|
V
|
F
|
A
|
P
|
V
|
360 |
ECL3 | TM7 | ||||||||
T
|
E
|
E
|
Q
|
A
|
R
|
G
|
A
|
L
|
R
|
370 |
F
|
A
|
K
|
L
|
G
|
F
|
E
|
I
|
F
|
L
|
380 |
S
|
S
|
F
|
Q
|
G
|
F
|
L
|
V
|
S
|
V
|
390 |
H8 | |||||||||
L
|
Y
|
C
|
F
|
I
|
N
|
K
|
E
|
V
|
Q
|
400 |
S
|
E
|
I
|
R
|
R
|
G
|
W
|
H
|
H
|
C
|
410 |
R
|
L
|
R
|
R
|
S
|
L
|
G
|
E
|
E
|
Q
|
420 |
C-term | |||||||||
R
|
Q
|
L
|
P
|
E
|
R
|
A
|
F
|
R
|
A
|
430 |
L
|
P
|
S
|
G
|
S
|
G
|
P
|
G
|
E
|
V
|
440 |
P
|
T
|
S
|
R
|
G
|
L
|
S
|
S
|
G
|
T
|
450 |
L
|
P
|
G
|
P
|
G
|
N
|
E
|
A
|
S
|
R
|
460 |
E
|
L
|
E
|
S
|
Y
|
C
|
DIAGRAMS
Pick color:
Invitro Mutant Data: Increased binding/potency: >5-fold, >10-fold; Reduced binding/potency: >5-fold, >10-fold; No/low effect (<5-fold); and N/A
Pick color:
Invitro Mutant Data: Increased binding/potency: >5-fold, >10-fold; Reduced binding/potency: >5-fold, >10-fold; No/low effect (<5-fold); and N/A
MUTATIONS
PHYSIOLOGICAL LIGANDS
gastric inhibitory polypeptide